About UNI HEALTH Company

Big Health International Group Holdings Limited (“the Company”, together with its subsidiaries, the “Group” and its subsidiaries (“the Group”), stock code: 2211), aims at huge market opportunities in the field of big health, strives to build an international health brand operator, and has become a leading practitioner of the “Internet+Big Health” strategy, and an industry leader in developing the industrial chain ecosystem through finance and capital. The Company is one of the leading pharmaceutical retailers and distributors in the Northeast region of the People's Republic of China (“China”). The Group has an excellent pharmaceutical retail chain network in Northeast China and is one of the largest private pharmaceutical distributors in Northeast China. As of the date of this annual report, the Group has 251 retail pharmacies, mainly located in northeast China. It has about 1,656 active distributors and 2,555 employees nationwide, and has set up five large-scale logistics storage and transportation centers in Shijiazhuang, Shenyang, Changchun, Harbin and Jiamusi, building a high-quality distribution system covering the whole country and northeast China. As a basic business segment, the Group's pharmaceutical retail and distribution (including import and export trade) mainly deals in product categories, including prescription drugs, non-prescription drugs (proprietary Chinese medicines, chemical preparations, antibiotics, biochemicals), traditional Chinese medicine tablets, biological products, anabolic agents, peptide hormones, blood products, disinfectants, medical devices, family planning products (contraceptives and appliances), pre-packaged food, dairy products (including infant formula), health food, health products, cosmetic packaging and daily necessities. The Group continues to give full play to the core advantages of brand products, expand the scope of brand product cooperation, use course training in business schools to provide more value-added services to employees, customers and consumers. Based on its expertise in drug retail and distribution, the Group is committed to bringing more health products into the sales pipeline and implementing the big health industry concept. At the same time, the Group is actively expanding the upstream ecological chain to the construction of a Chinese herbal medicine planting base and the production of vegetable capsules. The Group actively explores online pharmacies, cross-border e-commerce, influencer drainage and other “Internet +” fields, and promotes the “professional +” concept, introduces the “platform +” development concept, uses industry advantages to maintain the upstream and downstream ecosystems, cope with the “new normal” of the real economy, and takes the lead in implementing industrial upgrading and digital transformation in the industry.